New treatment proposed to prevent devastating intestinal inflammation in cancer patients

Prof. Ben-Neriah and Naama KanarekFebruary 23, 2014: Experimental work pointing to a therapy for alleviating mucositis — a common, severe side-effect of chemotherapy and irradiation of cancer patients or patients prepared for bone marrow transplantation — has been achieved by an international team of researchers from the US and Israel headed by Hebrew University scientists.

Mucositis is a strong inflammatory reaction of the mucosal lining of the digestive system, particularly the gut. Mucositis is often a major reason for premature suspension of anti-cancer therapy. As of today, there has been no effective means of preventing mucositis or its treatment.

The research group at the Hebrew University specializes in genetic engineering of mouse models (GEMMs) of inflammation and cancer. Naama Kanarek, a doctoral student at the Lautenberg Center for Immunology and Cancer Research and the Institute for Medical Research Israel-Canada at the Faculty of Medicine, constructed a mouse model designed to study the effect of deleting a gene encoding the enzyme beta-TrCP.

This enzyme was discovered in the laboratory of IMRIC’S Prof. Yinon Ben-Neriah 15 years ago, in collaboration with the Israeli Nobel Laureate Prof. Aaron Ciechanover — a Hebrew University alumnus — as a major regulator of inflammatory cascades.

Kanarek found that beta-TrCP deletion in the gut causes mucosal DNA damage, mimicking the effect of chemotherapy and irradiation. Similarly to human patients, she showed that a severe mucositis reaction occurred in mice who were genetically engineered to be beta-TrCP-deficient.

Tracing the pathological basis of the mouse mucositis revealed that the source of the problem was Interleukin-1 (IL-1 beta), a protein secreted by the stressed mucosa. IL-1 beta was found to abnormally open the gut lining, allowing gut bacteria to penetrate and destroy the gut interior. Most importantly was Kanarek’s observation that treating the mice with an antibody which blocks IL-1 beta prevents the onset of mucositis in the beta-TrCP-deficient mice.

Based on these findings, the researchers proposed that IL-1b beta blocking reagents, like Anakinra (Kineret), which is used for treating certain chronic inflammatory conditions like rheumatoid arthritis and Crohn’s disease, should be tried for preventing mucositis in humans.

The work of the researchers was published recently in the American journal PNAS.

Source: Marketing & Communication, Hebrew University